Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models

Neuropharmacology

Volumn 38, Issue 12, 1999, Pages 1831-1839

  Klodzińska, Aleksandra ^a   Chojnacka Wójcik, Ewa ^a   Palucha, Agnieszka ^a   Brański, Piotr ^a   Popik, Piotr ^a   Pilc, Andrzej ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Anxiety; Behavioural despair test; Conflict drinking test; Dependence; Depression; Four plate test; LY 354740; mGlu II receptors; Morphine withdrawal; Tail suspension

Indexed keywords

5 HYDROXYTRYPTOPHAN; DIAZEPAM; EGLUMETAD; GLUTAMATE RECEPTOR AGONIST; IMIPRAMINE; METABOTROPIC RECEPTOR; MORPHINE; NALOXONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR; CONFLICT; CONTROLLED STUDY; FLUID INTAKE; FORCED SWIMMING TEST; IMMOBILIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MORPHINE ADDICTION; MOTOR COORDINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; WITHDRAWAL SYNDROME;

ANIMALS; ANTI-ANXIETY AGENTS; BEHAVIOR, ANIMAL; BICYCLO COMPOUNDS; CONFLICT (PSYCHOLOGY); DRINKING; MALE; MICE; MICE, INBRED C57BL; MORPHINE; MOTOR ACTIVITY; NARCOTICS; RATS; RATS, WISTAR; RECEPTORS, METABOTROPIC GLUTAMATE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0344980107     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00066-0     Document Type: Article

References (50)

1. Aron C., Simon P., Larousse C., Boissier J.R. Evaluation of a rapid technique for detecting minor tranquilizers. Neuropharmacology. 10:1971;459-469.
2. Bond A., Monn J.A., Lodge D. A novel orally active group 2 metabotropic glutamate receptor agonist: LY354740. Neuroreport. 8:1997;1463-1466.
3. Cappendijk S.L., de Vries R., Dzoljic M.R. Excitatory amino acid receptor antagonists and naloxone-precipitated withdrawal syndrome in morphine-dependent mice. Eur. Neuropsychopharmacol. 3:1993;111-116.
4. Chojnacka-Wójcik E., Tatarczyńska E., Pilc A. Anxiolytic-like effects of metabotropic glutamate antagonist (RS)-alpha-methylserine-O-phosphate in rats. Polish J. Pharmacol. 48:1997;507-509.
5. Chojnacka-Wójcik E., Tatarczyńska E., Pilc A. The anxiolytic-like effect of metabotropic glutamate receptor antagonists after intrahippocampal injection in rats. Eur. J. Pharmacol. 319:1997;153-156.
6. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev. Pharmacol. Toxicol. 37:1997;205-237.
7. Danysz W., Parsons C.G., Bresnik I., Quack G. Glutamate in CNS disorders. Drug News Perspect. 8:1996;261-277.
8. Fundytus M.E., Coderre T.J. Effect of activity at metabotropic, as well as ionotropic (NMDA), glutamate receptors on morphine dependence. Br. J. Pharmacol. 113:1994;1215-1220.
9. Fundytus M.E., Coderre T.J. Attenuation of precipitated morphine withdrawal symptoms by acute icv administration of a group IImGluR agonist. Br. J. Pharmacol. 121:1997;511-514.
10. Fundytus M.E., Ritchie J., Coderre T.J. Attenuation of morphine withdrawal symptoms by subtype-selective metabotropic glutamate receptor antagonists. Br. J. Pharmacol. 120:1997;1015-1020.
11. Glaum S.R., Miller R.J. Acute regulation of synaptic transmission by metabotropic glutamate receptors. Conn P.J., Patel J. The Metabotropic Glutamate Receptors. 1994;147 Humana Press, Totowa, NJ.
12. Helton D.R., Tizzano J.P., Monn J.A., Schoepp D.D., Kallman M.J. LY354740: a metabotropic glutamate receptor antagonist which ameliorated symptoms of nicotine withdrawal in rats. Neuropharmacology. 36:1997;1511-1516.
13. Helton D.R., Tizzano J.P., Monn J.A., Schoepp D.D., Kallman M.J. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J. Pharmacol. Exp. Therap. 284:1998;651-660.
14. Jessa M., Nazar M., Bidzinski A., Plaznik A. The effects of repeated administration of diazepam, MK-801 and CGP 37849 on rat behavior in two models of anxiety. Eur. Neuropsychopharmacol. 6:1996;55-61.
15. Layer R.T., Popik P., Nowak G., Paul I.A., Trullas R., Skolnick P. A unified theory of antidepressant action: Evidence from adaptation of the N-methyl-D-aspartate (NMDA) receptor complex following chronic antidepressant treatments. Soria B., Cena V. Ion Channel Pharmacology. 1998;438-457 Oxford University Press, London.
16. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav. Pharmacol. 8:1997;523-532.
17. Lovinger D.M., McCool B.A. Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3. J. Neurophysiol. 73:1995;1076-1083.
18. Manzoni O.J., Castillo P.E., Nicoll R.A. Pharmacology of metabotropic glutamate receptors at the mossy fiber synapses of the guinea pig hippocampus. Neuropharmacology. 34:1995;965-971.
19. Marek P., Ben-Eliyahu S., Gold M., Liebeskind J.C. Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res. 547:1991;77-81.
20. Marvizon J.C., Lewin A.H., Skolnick P. 1-Aminocyclopropane carboxylic acid: a potent and selective ligand for the glycine modulatory site of the N-methyl-D-aspartate receptor complex. J. Neurochem. 52:1989;992-994.
21. Mc Geer P.L., Eccles J.C, Mc Geer E.G Molecular Neurobiology of the Mammalian Brain. 1987;Plenum Press, New York.
22. Monaghan D.T., Bridges R.J., Cotman C.W. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 29:1989;365-402.
23. Monn J.A., Valli M.J., Massey S.M., Wright R.A., Salhoff C.R., Johnson B.G., Howe T., Alt C.A., Rhodes G.A., Robey R.L., Griffey K.R., Tizzano J.P., Kallman M.J., Helton D.R., Schoepp D.D. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): A potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J. Med. Chem. 40:1997;528-537.
24. Palucha A., Branski P., Tokarski K., Bijak M., Pilc A. Influence of imipramine on the group I of glutamate metabotropic receptors in CA1 region of hippocampus. Polish J. Pharmacol. 49:1998;495-497.
25. Petralia R.S., Wang Y.X., Niedzielski A.S., Wenthold R.J. The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience. 71:1996;949-976.
26. Pilc A., Legutko B. Antidepressant treatment influences cyclic AMP accumulation induced by excitatory amino acids in rat brain. Polish J. Pharmacol. 47:1995;359-361.
27. Pilc A., Legutko B. The influence of prolonged antidepressant treatment on the changes in cyclic AMP accumulation induced by excitatory amino acids in rat cerebral cortical slices. Neuroreport. 7:1995;85-88.
28. Pilc A., Branski P., Palucha A., Tokarski K., Bijak M. Antidepressant treatment influences group I of glutamate metabotropic receptors in slices from hippocampal CA1 region. Eur. J. Pharmacol. 349:1998;83-87.
29. Pin J.P., Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology. 34:1995;1-26.
30. Pollard G.T., Howard J.L. Effects of drugs on punished behavior: pre-clinical test for anxiolytics. Pharmacol. Therapeut. 45:1990;403-424.
31. Popik P., Mamczarz J., Fraczek M., Widla G., Hesselink M., Danysz W. Inhibition of reinforcing effects of morphine and naloxone-precipitated opioid withdrawal by novel glycine site and uncompetitive NMDA receptor antagonists. Neuropharmacology. 37:1998;1033-1042.
32. Popik P., Skolnick P. The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol. Biochem. Behav. 53:1996;791-798.
33. Porsolt R.D., Bertin A., Jalfre M. Behavioural despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Thererapeut. 229:1977;327-336.
34. Przegaliński E., Tatarczyńska E., Chojnacka-Wójcik E. Anticonflic effect of ipsapirone, buspirone and gepirone is not mediated by their common metaboilte 1-(2-pyrimidinyl)piperazine. J. Psychopharmacol. 3:1989;180-185.
35. Przegaliński E., Tatarczyńska E., Dereń-Wesolek A., Chojnacka-Wójcik E. Anticonflict effects of a competitive NMDA receptor antagonist and a partial agonist at strychnine-insensitive glycine receptors. Pharmacol. Biochem. Behav. 54:1996;73-77.
36. Przegaliński E., Tatarczyńska E., Dereń-Wesolek A., Chojnacka-Wójcik E. Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist. Neuropharmacology. 36:1997;31-37.
37. Rowland N.E., Caputo F.A., Fregly M.J. Water intake induced in rats by serotonin and 5-hydroxytryptophan: different mechanisms? Brain Res. Bull. 18:1987;501-508.
38. Schoepp D.D., Johnson B.G., Monn J.A. Inhibition of cyclic AMP formation by a selective metabotropic glutamate receptor agonist. J. Neurochem. 58:1992;1184-1186.
39. Skolnick P., Layer R.T., Popik P., Nowak G., Paul I.A., Trullas R. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: Implications for the pharmacotherapy of depression. Pharmacopsychiatry. 29:1996;23-26.
40. Stefanski R., Palejko W., Kostowski W., Plaznik A. The comparison of benzodiazepine derivatives and serotonergic agonists and antagonists in two animal models of anxiety. Neuropharmacology. 31:1992;1251-1258.
41. Stephens D.N. A glutamatergic hypothesis of drug dependence: extrapolations from benzodiazepine receptor ligands. Behav. Pharmacol. 6:1995;425-446.
42. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology. 85:1985;367-370.
43. Trujillo K.A., Akil H. Excitatory amino acids and drugs of abuse: a role for N-methyl-D-aspartate receptors in drug tolerance, sensitization and physical dependence. Drug Alcohol Dependence. 38:1995;139-154.
44. Trullas R., Folio T., Young A., Miller R., Boje K., Skolnick P. 1-aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models. Eur. J. Pharmacol. 203:1991;379-385.
45. Trullas R., Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 185:1990;1-10.
46. Ugolini A., Bordi F. Metabotropic glutamate group II receptors are responsible for the depression of synaptic transmission induced by ACPD in the dentate gyrus. Eur. J. Pharmacol. 294:1995;403-410.
47. Vogel J.R., Beer B., Clody D.E. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia. 21:1971;1-7.
48. Wiley J.L., Balster R.L. NMDA antagonists: a novel class of anxiolytics? Hamon M., Ollat H., Thiebot M.-H. Anxiety: Neurobiology, Clinical and Therapeutic Perspectives. 1993;177-184 John Libby Eurotext/Colloque UNSERM 232, Montrouge, France.
49. Willner P., Papp M. Animals models to detect antidepressants: are new strategies necessary to detect new agents? Skolnick P. Antidepressants: New Strategies. 1997;213-234 The Human Press, Totowa, NJ.
50. Wroblewski J.T., Danysz W. Modulation of glutamate receptors: molecular mechanisms and functional implications. Annu. Rev. Pharmacol. Toxicol. 29:1989;441-474.